Purchase the ATMP report at www.evernowpublishing.com

Subscribe to MedNous and get ahead in the business of medical innovation. Subscribe now.

The latest MedNous journal. Subscribe to download.

BioInvent rights issue is underway

Country: Sweden

BioInvent International AB plans to raise SEK 75 million (€8 million) in a rights issue to investors to further develop its anti-cancer antibodies. Shareholders of record on 24 April will receive rights to purchase four new shares for every nine held.

Read more

New deals for AZ in immuno-oncology

Country: United Kingdom

AstraZeneca Plc has announced two new deals in immuno-oncology that will exploit the potential of its checkpoint inhibitor MED14736 in both haematological and solid tumour cancers. The monoclonal antibody is currently in Phase 3 development for non-small cell lung cancer and head and neck cancer.

Read more

Novartis hit by strong dollar

Country: Switzerland

Read more

Roche reports on first quarter sales

Country: Switzerland

Read more

Actelion posts good first quarter results

Country: Switzerland

Read more

ThromboGenics revives drug programme

Country: Belgium

Read more

EMA holds workshop for SMEs

Country: United Kingdom

Read more

Biocartis in initial public offering

Country: Belgium

Read more

Schizophrenia compound progressed

Country: United Kingdom

Read more

Horizon Discovery reports higher revenue

Country: United Kingdom

Read more

Study points to common genetic faults in cancer

Country: United Kingdom

Read more

New device for liver transplantation

Country: United Kingdom

Read more

Looking for more?

Visit our news section for more articles.

News
Our full Mednous news archive
Appointments
Latest industry appointments
Events
A list of upcoming industry events

About Mednous

MedNous is a print publication and a website for everyone involved in medical research in Europe.

Read more

Free Article

How biopharma is exploiting the microbiome

MicrobiomeApr2015.pdf

Highlights of the April 2015 MedNous issue

The April 2015 MedNous features:

Latest Mednous cover
  • Business Strategy
    How biopharma is exploiting the microbiome
  • Health Technology Assessment
    Case study: Sovaldi is assessed in Europe
    By Karen Finn
  • Regenerative Medicine
    Diabetes findings exploited
  • Commentary
    Engineered cell therapies
    by Stefanos Theoharis
  • Stock Market Performance
    Success pushes European biotechs higher

The latest MedNous journal. Subscribe to download.